At the news
? BULLISHIMPACT 7/10 8-K filed Aug 28, 2026 at 09:21 ET
Cytokinetics announced positive Phase 3 results from ACACIA-HCM, the first-ever successful trial in non-obstructive HCM. The trial met both dual primary endpoints with statistical significance, and the company plans to submit a supplemental New Drug Application to the FDA in Q4 2026. This expands the potential label for aficamten (MYQORZO) from obstructive to the full spectrum of symptomatic HCM, representing a major pipeline catalyst.
- ACACIA-HCM met both dual primary endpoints: KCCQ-CSS (p=0.021) and pVO2 (p=0.003) at Week 36 vs placebo
- Supplemental NDA for aficamten in non-obstructive HCM to be submitted to FDA in Q4 2026
- Results presented at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine
- Aficamten is already approved as MYQORZO for obstructive HCM in the U.S., China, EU, and UK
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access